Replies to post #63626 on Biotech Values

[oldberkeley]

>The 200 DMA vs buyout price for biotechs will just not pan out...

You're probably right, I was just exploring a line of thought that was suggested by a post on the GTCB board.

I think we'd both agree with what Dew recently wrote:

The stock market can be notoriously inefficient, but the market for buying and selling drugs and drug companies is generally quite efficient.